Emine KOCABAŞ, Ümit ÇELİK

Çocuklarda kronik akciğer hastalıklarının antibiyotik tedavisinde yeni yaklaşımlar

Kronik akciğer hastalıkları, çocukluk çağında hem hasta hem de hekim için önemli sağlık sorunlarından biridir. Tanı yöntemlerindeki gelişmeler sonucu, bu hastalıkların erken dönemde tanımlanması, gelişebilecek komplikasyonların erken tanısı, aşılama yöntemlerinde ilerlemeler ve erken antibiyotik tedavileri sonucu hastaların yaşam sürelerindeki uzama, bu hastalıkları sadece çocukların değil, erişkinlerin de önemli bir sağlık sorunu haline getirilmiştir. Hastalığın prognozunu etkileyen en önemli etmenlerden birisi, üzerine eklenen infeksiyonlardır. Bu yazıda; çocuklarda ve erişkinlerde sık görülen kronik akciğer hastalıklarından olan kistik fibrozis, bronşektazi ve allerjik bronkopulmoner aspergillozda antibiyotik kullanım ilkeleri bu konudaki son gelişmeler eşliğinde tartışılmıştır.

New approaches in antibiotic therapies in chronic pulmonary diseases

Chronic lung diseases are one of the considerable problems in childhood both for physcians and patients. Due to early diagnosis of illness and complications; advances at vaccination methods and antibiotic therapies; life period of patients have been prolonged so not only at childhood but at adults, chronic lung diseases seem to be important healthy problem. One of the most important factors affectting to prognosis of the diseases are concominant infections. This review is an argument of antibiotic usage regimens at cystic fibrosis, bronchiectasis and allergic bronchopulmonary aspergillosis which are the most usual chronic lung diseases seen at childhood and adults.

PDF

___

1. Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: Chromosome walking and jumping. Science 1989; 245: 1059-65.
2. Slieker MG, Viterwool CS, Sinaasappel M, et al. Birth prevalence and survival in cystic fibrosis: A national cohort study in the Netherlands. Chest 2005; 128: 2309-15.
3. Mahadeva R, Webb K, Westerbeek RC, et al. Clinical outcome in relation to care in centres specialising in cystic fibrosis: Cross sectional study. BMJ 1998; 316: 1771-5.
4. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918-51.
5. Brennan AL, Geddes DM. Cystic fibrosis. Curr Opin Infect Dis 2002; 15: 175-82.
6. Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001; 32:356-66.
7. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100.
8. Simon RH. Treatment of cystic fibrosis. www.uptodate.com
9. Smith AL, Doershuk C, Goldmann D, et al. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999; 134: 413-21.
10. Rey E, Treluyer JM, Pons G. Drug disposition in cystic fibrosis. Clin Pharmacokinet 1998; 35: 313-29.
11. Bolton CE, Ionescu AA, Evans WD, et al. Altered tissue distribution in adults with cystic fibrosis. Thorax 2003;58: 885-9.
12. Touw DJ. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm World Sci 1998; 20: 149-60.
13. Smyth A, Tan KH, Hyman-Taylor P, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis the TOPIC study: A randomised controlled trial. Lancet 2005; 365: 573-8.
14. Breen L, Aswani N. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev 2001; (4): CD002767.
15. Diver JM, Schollaardt T, Rabin HR, et al. Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. Antimicrob Agents Chemother 1991; 35: 1538-46.
16. Sheldon CD, Assoufi BK, Hodson ME. Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. Respir Med 1993; 87: 587-93.
17. Szaff M, Hoiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983; 72: 651-7.
18. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340: 23-30.
19. Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121:55-63.
20. Alothman GA, Ho B, Alsaadi MM, et al. Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 2005;127: 522-9.
21. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002; 20: 658-64.
22. Smyth A, Walters S. Prophylactic antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003; (3):CD001912.
23. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23: 330-5.
24. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001; 358: 983-4.
25. Aaron SD, Ferris W, Henry DA, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000; 161: 1206-12.
26. Holmes A, Nolan R, Taylor R, et al. An epidemic of Burkholderia cepacia transmitted between patients with and without cystic fibrosis. J Infect Dis 1999; 179: 1197-205.
27. Nadesalingam K, Conway SP, Denton M. Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis. J Cyst Fibros. 2005; 4: 49-52.
28. Olivier KN, Yankaskas JR, Knowles MR. Nontuberculous mycobacterial pulmonary disease in cystic fibrosis. Semin Respir Infect 1996; 11: 272-84.
29. Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria: I: Multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 828-34.
30. Esther CR Jr, Henry MM, Molina PL, Leigh, MW. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol 2005; 40: 39-44.
31. Doring G, Jansen S, Noll H, et al. Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Pediatr Pulmonol 1996; 21:90-100.
32. McArdle JR, Talwalkar JS. Macrolides in cystic fibrosis. Clin Chest Med 2007; 28: 347-60.
33. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 2003; 290: 1749-56.
34. Equi A, Balfour Lynn IM, Bush A, et al. Long term azithromycin in children with cystic fibrosis: A randomised, placebo controlled crossover trial. Lancet 2002; 360:978-84.
35. Barker AF. Bronchiectasis. N Engl J Med 2002; 346:1383-93.
36. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1277-84.
37. Angrill J, Agusti C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: Microbiological pattern and risk factors. Thorax 2002; 57: 15-9.
38. Tsang KW, Chan WM, Ho PL, et al. A comparative study on the efficiacy of levofloxasin and ceftazidime in acute exacerbation of bronchiectasis. Eur Respir J 1999; 14:1206-9.
39. Bilton D, Henig N, Morissey B, et al. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006; 130: 1503-10.
40. Rayner CF, Tillotson C, Gole PJ, et al. Efficacy and safety of long-term ciprofloxacin in the management of severe bronchiectasis. J Antimicrob Chemother 1994; 34: 149-56.
41. Currie DC, Garbett ND, Chan KL. Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. Q J Med 1990; 76: 799-816.
42. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162: 481-5.
43. Wilson CB, Jones PW, O’Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997; 10: 1754-60.
44. Stevens DA, Schwartz HJ, Lee YJ, et al. A randomized trial of itraconazloe in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342: 756-62.
45. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110: 685-92.
46. Zander DS. Allergic bronchopulmonary aspergillosis: An overview. Arch Pathol Lab Med 2005; 129: 924-8.
47. Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37: 225-64.
48. Greenberger PA, Patterson R. Allergic bronchopulmonary aspergillosis and the evaluation of the patient with asthma. J Allergy Clin Immunol 1988; 81: 646-50.
49. Ricketti AJ, Greenberger PA, Patterson R. Serum IgE as an important aid in management of allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 1984; 74:68-71.
50. Marchant JL, Warner JO, Bush A. Rise in total IgE as an indicator of allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax 1994; 49: 1002-5.
51. Wark PA, Gibson PG, Wilson AJ. Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev 2004; (3): CD001108.
52. Salez F, Brichet A, Desurmont S, et al. Effects of itraconazole therapy in allergic bronchopulmonary aspergillosis. Chest 1999; 116: 1665-8.
53. Wark PA, Hensley MJ, Saltos N, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: A randomized controlled trial. J Allergy Clin Immunol 2003; 111: 952-7.
54. Bolland MJ, Bagg W, Thomas MG, et al. Cushing’s syndrome due to interaction between inhaled corticosteroids and itraconazole. Ann Pharmacother 2004; 38: 46-9.
55. Hilliard T, Edwards S, Buchdahl R, et al. Voriconazole therapy in children with cystic fibrosis. J Cyst Fibros 2005; 4: 215-20.
56. Vlahakis NE, Aksamit TR. Diagnosis and treatment of allergic bronchopulmonary aspergillosis. Mayo Clin Proc 2001; 76: 930-8.